ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 1555 • ACR Convergence 2024

    Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy

    Vibeke Strand1, Kenneth Kalunian2, Ian Bruce3, Caroline Seo4, Kai Wai Lee5, Jacob Knagenhjelm6 and Catharina Lindholm6, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2University of California San Diego, La Jolla, CA, 3Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 4BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, 5Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2  We previously demonstrated that, compared with placebo, a…
  • Abstract Number: 1688 • ACR Convergence 2024

    Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses

    Jack Arnold1, Lucy Carter1, Yuzaiful Yusof2, Zoe Wigston2, Daniel Toro Dominguez3, Samuel Relton4, Guillermo Barturen5, Marta Alarcon-Riquelme6 and Edward Vital7, and PRECISESADS consortium, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, 3Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, 4Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, 5Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 6Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom

    Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
  • Abstract Number: 1807 • ACR Convergence 2024

    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus

    Takehiro Hirayama1, Hyota Takamatsu2 and Atsushi Kumanogoh3, 1Osaka university, ibaraki city, Japan, 2National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, 3Osaka University, Osaka, Japan

    Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
  • Abstract Number: 1879 • ACR Convergence 2024

    Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023

    Mario Bautista-Vargas1, Adrian Romero-Ocampo2, Juan José Pino Vélez3, juliana Muñoz-Bedoya4 and Diego Rosselli5, 1Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, 2Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, 3Universidad de Antioquia, Envigado, Antioquia, Colombia, 4Universidad Corpas, Bogotá, Colombia, 5Pontificia Universidad Javeriana, Bogotá, Colombia

    Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
  • Abstract Number: 2033 • ACR Convergence 2024

    Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?

    Hanna Caroline Antunes Dos Santos1, Zoraida Sachetto1, Rodrigo da rocha jorge1, Gabriela Vilaça Gutierrez1, Renata Froes Ramos de lima1, Ananda Ribeiro Fretes1, Maria Fernanda zacarin1, Roberto dos reis1 and Alisson Pugliesi2, 1Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil, 2Unicamp, Campinas, Brazil

    Background/Purpose: Ophthalmologists increasingly call rheumatologists for the evaluation and treatment of scleritis. Although they can be of immune etiology (systemic or restricted to the eye),…
  • Abstract Number: 2254 • ACR Convergence 2024

    A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers

    Cory Sellwood1, Minggeng Gao2, Sheen Zhang2, Mark Matijevic2, Stephen Wax3, Mason Yamashita2, Shan Yu2, Sujata Arora2 and Rachel Kirk2, 1New Zealand Clinical Research, Christchurch, New Zealand, 2Zenas BioPharma, Waltham, MA, 3Former Employee of Zenas Biopharma, Newton, MA

    Background/Purpose: ZB004 is a bioengineered cytotoxic T-lymphocyte-associated antigen 4 ‑immunoglobulin (CTLA-4-Ig) fusion protein. Its mechanism of action is selective inhibition of T lymphocyte (T cell)…
  • Abstract Number: 2442 • ACR Convergence 2024

    Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study

    Santiago Dans Caballero1, Clementina López Medina2, Chary Lopez-Pedrera3, Carlos Perez-Sanchez4, Alejandro Escudero-Contreras5 and Rafaela Ortega-Castro6, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2Reina Sofia University Hospital, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 5Reina Sofia University Hospital, Córdoba, Spain, 6Hospital Reina Sofía, Cordoba, Andalucia, Spain

    Background/Purpose: Systemic sclerosis is a systemic autoimmune disease with multiorgan involvement. Its pathophysiology is based on three pillars: vasculopathy, fibrosis, and autoimmunity. Despite advances in…
  • Abstract Number: 2600 • ACR Convergence 2024

    Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus

    Qiaolin Wang1, Yutong Wu2, Qianjin Lu1 and Ming Zhao1, 1Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic), 2Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Nanjing, China (People's Republic)

    Background/Purpose: Dysregulation of intestinal γδT cells orchestrates the pathogenesis of various autoimmune disorders, however, its involvement in systemic lupus erythematosus (SLE) etiology remains elusive.Methods: Employing single-cell sequencing, we…
  • Abstract Number: 0015 • ACR Convergence 2024

    Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution

    Ana Merino Vico1, Yosta Vegting1, Aldo Jongejan1, Jan Piet van Hamburg1, Perry moerland1, Sander Tas2 and Marc Hilhorst1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
  • Abstract Number: 0151 • ACR Convergence 2024

    Immunoproteomic Profiling of Antibodies in Autoimmune Diseases

    Choa Yun1, Ji Qiu2, M. Constanza Camargo3, Lusheng Song2, Joshua LaBaer2, Hyokyoung G. Hong3, Eric A. Engels3, Maddy Edie-Booker4, Adam Schiffenbauer5, Lisa Rider6, Frederick Miller7, Sarfaraz Hasni5, Blake M. Warner5, Mārcis Leja8 and Minkyo Song9, 1National Institute on Aging, Rockville, MD, 2Arizona State University, Tempe, 3National Cancer Institute, Rockville, 4National Institute on Aging, Baltimore, MD, 5NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, 6NIEHS, NIH, Garrett Park, MD, 7NIH, NIEHS, Chapel Hill, NC, 8University of Latvia, Rīga, Latvia, 9National Institutes on Aging, Baltimore, MD

    Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
  • Abstract Number: 0298 • ACR Convergence 2024

    RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults

    Miwa Haranaka1, Akinori Yamada2, Saki Takahashi2, Keisuke Gotanda2, Sonoko Nakano-Kanatani2, Nana Uemura2, Kensuke Ohnishi2, Masanobu Nishidate2, Ichio Ohnami2 and Megumi Kai3, 1Souseikai Hakata Clinic, Fukuoka, Japan, 2Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 3Oita University, Oita, Japan

    Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
  • Abstract Number: 0407 • ACR Convergence 2024

    Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India

    Lekshmi Minikumari Rahulan1, Able Lawrence2 and Amita Aggarwal3, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 2SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Familial aggregation of autoimmune disease as well as co-occurrence of multiple autoimmune diseases in one individual is known and it suggests a shared genetic…
  • Abstract Number: 0618 • ACR Convergence 2024

    Comparison of Cell Type-Specific Polygenic Risk in Systemic Lupus Erythematosus Patient and Healthy Controls

    Liyoung Kim1, Vitor Aguiar2, Daniela Fernandez-Salinas3, Jeffrey Sparks4, Peter Nigrovic1, Joyce Chang2 and Maria Gutierrez-Arcelus2, 1Boston Children's Hospital, Brookline, MA, 2Boston Children's Hospital, Boston, MA, 3Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Polygenic risk scores quantify the composite impact of numerous genetic variants to predict disease risk. However, conventional polygenic risk scores have limitations in revealing…
  • Abstract Number: 0782 • ACR Convergence 2024

    30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis

    Sylvia Posso1, Jane Buckner2, Montserrat Anguera3 and Nikhil Jiwrajka4, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3University of Pennsylvania, Philadelphia, PA, 4Hospital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Systemic sclerosis (SSc) is a heavily female-biased systemic autoimmune disease associated with significant morbidity and mortality due to fibrosis of the skin and vital…
  • Abstract Number: 0891 • ACR Convergence 2024

    Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells

    Jacquelyn Nestor1, Rachelly Normand1, Wamia Said1, Sergio Aguilar2, Nandini Samanta1, Sidney Martin1, Roya Best1, Hoang Anh Tran1, Adrien Antoinette1, Eilish Dillon3, Devin King3, April Jorge4, Maureen Leonard4, Pritha Sen3, Kerry Reynolds4, John Stone5, Michelle Rengarajan1, Tanuja Chitnis6, Kevin Wei7, Deepak Rao3, Andrew Luster8, Gary Reynolds1 and Alexandra-Chloe Villani1, 1Massachusetts General Hospital, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA, 2National Center for Genomic Analysis, Barcelona, Spain, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital , Harvard Medical School, Concord, MA, 6Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 8Massachusetts General Hospital, Charlestown, MA

    Background/Purpose: Rheumatologic diseases are characterized by distinct clinical presentations and patterns of organ involvement, yet share many genetic risk factors and treatment responses. This suggests…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology